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Abstract 
Background: Sepsis is one of the most common diseases that seriously threaten human health. Although a large 
number of markers related to sepsis have been reported in the last two decades, the diagnostic accuracy of these 
biomarkers remains unclear due to the lack of similar baselines among studies. Therefore, we conducted a large 
systematic review and meta‑analysis to evaluate the diagnostic value of biomarkers from studies that included non‑
infectious systemic inflammatory response syndrome patients as a control group.
Methods: We searched Medline, Embase and the reference lists of identified studies beginning in April 2014. The last 
retrieval was updated in September 2016.
Results: Ultimately, 86 articles fulfilled the inclusion criteria. Sixty biomarkers and 10,438 subjects entered the final 
analysis. The areas under the receiver operating characteristic curves for the 7 most common biomarkers, including 
procalcitonin, C‑reactive protein, interleukin 6, soluble triggering receptor expressed on myeloid cells‑1, presepsin, 
lipopolysaccharide binding protein and CD64, were 0.85, 0.77, 0.79, 0.85, 0.88, 0.71 and 0.96, respectively. The remain‑
ing 53 biomarkers exhibited obvious variances in diagnostic value and methodological quality.
Conclusions: Although some biomarkers displayed moderate or above moderate diagnostic value for sepsis, the 
limitations of the methodological quality and sample size may weaken these findings. Currently, we still lack an ideal 
biomarker to aid in the diagnosis of sepsis. In the future, biomarkers with better diagnostic value as well as a com‑
bined diagnosis using multiple biomarkers are expected to solve the challenge of the diagnosis of sepsis.
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Background
Epidemiological surveys indicate that sepsis is the lead-
ing cause of non-cardiac death in intensive care units and 
causes at least 30% of the deaths in patients who are sep-
tic (Levy et al. 2010). Along with the aging of the popula-
tion, the incidence of sepsis shows an obvious increase in 
countries around the world (Wafaisade et al. 2011; Mar-
tin et al. 2003; Angus et al. 2001). An important aspect of 
improving survival rates in septic patients is early diag-
nosis, which is helpful to ensure timely treatment and 
to avoid deterioration of organ function. The classical 
method of diagnosis is based on signs of an inflamma-
tory response and microbial cultures. However, doctors 
must wait for several days before getting culture results, 
and what is worse, negative culture results account for 
30–40%. Because microbial cultures have the features 
of being time-consuming and having a low positive rate 
as well as being non-specific for systemic inflammatory 
response syndrome (SIRS), many patients may lose the 
opportunity of timely and effective treatment. Unlike 
microbial culture, biomarkers, primarily from the blood, 
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increase in the early stage of the inflammatory response 
and show different expression between non-infectious 
inflammation and sepsis. Over the last 20  years, many 
researchers have been dedicated to finding blood bio-
markers for the early diagnosis of infection or sepsis, 
and they have obtained a substantial number of research 
results. However, due to the large amounts of experimen-
tal data and the inconsistency of the baselines among 
these studies, it is difficult for medical researchers and 
workers to make comparisons across various biomarkers 
or to identify biomarkers with potential diagnostic value. 
Therefore, we performed a large-scale meta-analysis to 
summarize potential biomarkers for the differential diag-
nosis between non-infectious SIRS and sepsis.
Methods
Literature search
We conducted the first systematic retrieval from PubMed 
and Embase in April 2014. The basic retrieval scheme 
included the following three search keywords: ‘sepsis’, 
‘systemic inflammatory response syndrome’ and ‘diag-
nosis’. Then, we excluded ‘review’, ‘erratum’, ‘editorial’ and 
‘letter’ from the retrieval results. In addition, the refer-
ence lists of the included original studies and relevant 
meta-analysis articles were examined for any eligible doc-
uments that were missed. The last retrieval was updated 
in September 2016. The study protocol was approved 
by the ethics committee affiliated with Daping Hospital 
and did not require written informed consent from the 
patients.
Selection criteria
Articles were included if they evaluated the diagnostic 
accuracy of biomarkers for distinguishing patients with 
sepsis from those with non-infectious SIRS. Sepsis was 
defined as the coexistence of SIRS with infection, accord-
ing to the diagnostic criteria proposed by the American 
College of Chest Physicians and the Society of Critical 
Care Medicine (Bone et  al. 1992). We excluded articles 
that lacked non-infectious SIRS patients as a control 
group. We also eliminated studies with immunocom-
promised patients, hematologic patients or pediatric 
patients. Moreover, articles that could not provide suffi-
cient data to build a 2 ×  2 contingency table were like-
wise excluded.
Data collection and quality assessment
The data were extracted independently by two review-
ers (YL and WX) using a pre-designed Microsoft Excel 
spreadsheet table that included the categories of method-
ological quality, methods of biomarker detection, features 
of the participants and results of diagnostic accuracy. 
If needed, the authors were contacted for any missing 
information. We evaluated the quality of the included 
studies according to the Quality Assessment of Diagnos-
tic Accuracy Studies (QUADAS). Because the analysis of 
the test results of the biomarkers did not involve clini-
cal data, we omitted item 12 of QUADAS in the quality 
assessment. Discrepancies between the two reviewers 
were resolved by discussion with the third author (SHW).
Data synthesis and statistical analysis
The scheme of the systematic review and meta-analy-
sis was implemented in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) statement (Moher et al. 2010). Stata 13.0 
software was used to perform the statistical analysis of 
the pooled data. We used an exact binomial rendition 
of the bivariate mixed-effects regression model for the 
synthesis of diagnostic test data (Reitsma et  al. 2005). 
I2 statistics were used to reflect the percentage of total 
variation across articles that were attributable to hetero-
geneity rather than chance. I2 values of 25, 50, and 75% 
describe the heterogeneity as low, moderate, and high, 
respectively (Higgins et al. 2003). If heterogeneity existed, 
and the number of studies was larger than 10, the poten-
tial reasons for heterogeneity were identified by meta-
regression. Publication bias was evaluated by employing 
a scatter plot with the inverse of the square root of the 
effective sample size versus the log diagnostic odds ratio, 
with a symmetrical funnel shape indicating less publica-
tion bias (Deeks et al. 2005).
Results
We retrieved articles from the PubMed and EMBASE 
databases. A total of 31,874 articles remained after 
duplicates were removed. Three hundred and thirty-two 
articles were preserved after examining the titles and 
abstracts. We further excluded 267 articles after review-
ing the full content. Sixty-five studies were included in 
the quantitative synthesis after the first retrieval. Finally, 
86 studies were included after two updated searches in 
February 2015 and September 2016 (Fig. 1) (Abidi et al. 
2008; Ahmadinejad et  al. 2009; Al-Nawas et  al. 1996; 
Anand et al. 2015; Balc et al. 2003; Barati et al. 2010; Bat-
tista et  al. 2016; Bell et  al. 2003; Beqja-Lika et  al. 2013; 
Carpio et al. 2015; Castelli et al. 2004; Clec’h et al. 2006; 
de Pablo et  al. 2013; Dorizzi et  al. 2006; Du et  al. 2003; 
Endo et al. 2012; Farag et al. 2013; Feng et al. 2012; Gaini 
et al. 2006; Garnacho-Montero et al. 2014; Gerrits et al. 
2013; Giamarellos-Bourboulis et  al. 2008; Gibot et  al. 
2004; Godnic et  al. 2015; Guven et  al. 2002; Han et  al. 
2016; Harbarth et al. 2001; Hoenigl et al. 2013; Hou et al. 
2012, 2016; Hsu et al. 2011; Ishikura et al. 2014; Ivancevic 
et al. 2008; Jekarl et al. 2013, 2014; Jiang et al. 2015; Kim 
and Zhang 2012; Kofoed et  al. 2007; Latour-Perez et  al. 
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2010; Lewis et  al. 2015; Li et  al. 2013a; Lin et  al. 2015; 
Matera et  al. 2013; Mat-Nor et  al. 2016; Mearelli et  al. 
2014; Meynaar et  al. 2011; Miglietta et  al. 2015; Miller 
et al. 1999; Muthiah et al. 2007, Naeini and Montazerol-
ghaem 2006; Oshita et al. 2010; Papadimitriou-Olivgeris 
et al. 2015; Ratzinger et al. 2013; Reichsoellner et al. 2014; 
Righi et al. 2014; Rivera-Chavez and Minei 2009; Rogina 
et al. 2014; Romualdo et al. 2014; Ruiz-Alvarez et al. 2009; 
Sakr et  al. 2008; Scherpereel et  al. 2006; Schulte et  al. 
2011; Selberg et  al. 2000; Seok et  al. 2012; Shozushima 
et  al. 2011; Sierra et  al. 2004; Su et  al. 2012, 2013; Sun-
gurtekin et  al. 2006; Suprin et  al. 2000; Takahashi et  al. 
2014; Talebi-Taher et al. 2014; Tan et al. 2016; Tian et al. 
2014; Tromp et al. 2012; Tsalik et al. 2012; Tsangaris et al. 
2009; Tugrul et al. 2002; Ulla et al. 2013; Vaschetto et al. 
2008; Vodnik et  al. 2013; Wang et  al. 2012, 2013; Wan-
ner et al. 2000; Xiao et al. 2015; Yousef et al. 2010). The 
study by Clec’h et al. reported results separately for med-
ical and surgical patients, and the study by Anand et al. 
reported results for positive and negative cultures. Fur-
thermore, the study by Lin et al. was divided into a train-
ing group and validation group. The results of these three 
studies were divided into six parts (Anand et  al. 2015; 
Clec’h et al. 2006; Lin et al. 2015).
The main characteristics of the studies are shown in 
Additional file  1: S1. Altogether, 10,438 patients with 
non-infectious SIRS or sepsis (including 30,043 test 
instances) and 60 biomarkers were included in the analy-
sis, of which 18,542 instances (61.72%) indicated sepsis, 
and 11,501 (38.28%) indicated a SIRS of non-infectious 
origin. The proportion of sepsis among the studies 
ranged between 16 and 93% (median 61%).
The methodological quality of the included studies was 
evaluated according to QUADAS. None of the studies 
fulfilled all of the items. The included studies fulfilled 766 
(69%) of the total 1118 items. The quality was poor for 
item 10 (index test results blinded), item 11 (reference 
standard results blinded) and item 13 (uninterpretable 
results) (Additional file  2: S2). Three biomarkers with 
more than 10 references, including procalcitonin (PCT), 
C-reactive protein (CRP) and interleukin 6 (IL-6), were 
evaluated for publication bias by using Deeks’ regression 
test of asymmetry (Fig. 2). There was significant publica-
tion bias for PCT (P = 0.02) but not for CRP (P = 0.62) 
and IL-6 (P = 0.70).
Fig. 1 Flow diagram of the study selection
Fig. 2 Funnel plots for detection of publication bias of PCT (a), CRP (b) and IL‑6 (c)
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Because of there being fewer than 4 references for 
each, the diagnostic accuracy data of 53 biomarkers 
could not be pooled by Stata 13.0 software. Thus, we 
pooled the sensitivity and specificity of 7 biomarkers, 
including PCT, CRP, IL-6, soluble triggering recep-
tor expressed on myeloid cells-1 (sTREM-1), presepsin 
(sCD14-ST), lipopolysaccharide binding protein (LBP) 
and CD64, with 7376, 5654, 3450, 831, 1510, 1136 and 
558 participants, respectively, and with the area under 
the receiver operating characteristic curve (AUC) being 
0.85, 0.77, 0.79, 0.85, 0.88, 0.71 and 0.96, respectively 
(Table 1). The forest plots for the biomarkers are shown 
in the Additional file 3: S3.
The biomarkers with less than 4 references are dis-
played in another table (Table  2). Several biomarkers 
presented high diagnostic values, with AUCs equal to or 
greater than 0.9 but fewer than 100 participants, includ-
ing decoy receptor 3 (DcR3), endocan, soluble intercellu-
lar adhesion molecule-1 (sICAM-1) and complement 3a 
(C3a) (with AUCs of 0.96, 0.92, 0.9 and 0.9, respectively).
Except for CD64, the remaining pooled data of 6 bio-
markers showed significant heterogeneity. We conducted 
a meta-regression analysis for 3 biomarkers (PCT, CRP 
and IL-6) for which the number of studies was larger 
than 10. Six factors were analyzed as potential sources 
of heterogeneity, including sample size, publication year, 
patient age, patient sex, proportion of patients with sep-
sis and methodological quality. Although the results of 
the meta-regression analysis showed that the race that 
was divided into Caucasian and Asian may be the het-
erogeneity source for PCT and CRP, the heterogeneity 
did not disappear in subgroup analysis by race. Therefore, 
there was no one factor that could satisfactorily explain 
the heterogeneity source of the three biomarkers.
Discussion
A total of 60 types of markers were included in our 
research. Most of the biomarkers had a small number 
of references. Six biomarkers with the largest number of 
participants or studies presented a moderate degree of 
diagnostic value, including PCT, CRP, IL-6, presepsin, 
LBP and sTREM-1, with AUC values of 0.85, 0.77, 0.79, 
0.88, 0.71 and 0.85, respectively. Presepsin and sTREM-
1, two popular research biomarkers over the last several 
years, presented diagnostic values similar to PCT. Sev-
eral biomarkers with AUCs greater than or equal to 0.9 
may be potential biomarkers for sepsis, including CD64, 
DcR3, endocan, sICAM-1 and C3a. However, the bio-
markers with the highest AUCs were described in studies 
with limited sample sizes and inadequate methodological 
quality.
Although the reference standard for SIRS and sepsis of 
the included studies was in accordance with the Ameri-
can College of Chest Physicians and the Society of Criti-
cal Care Medicine Consensus Conference, most studies 
did not provide details that described how the patients 
were diagnosed with SIRS or sepsis. In some studies, only 
patients with positive cultures were diagnosed with sep-
sis, while in other studies, all patients with positive cul-
tures or clinically suspected infections were diagnosed 
with sepsis. We believe that the cohort being investigated 
should include different types of patients, such as those 
with positive cultures and those with clinically confirmed 
infections. Only in this way can the results of the studies 
be more representative and have more clinical applica-
tion value. In addition, we believe studies should exclude 
the patients whose infection status cannot be confirmed, 
as these patients may lead to selective bias.
We evaluated the publication bias for three biomarkers, 
PCT, CRP and IL-6. Among them, the funnel plot of PCT 
presented publication bias. The PCT funnel plot showed 
a negative correlation between diagnostic value and 
sample size. In other words, large sample sizes tended 
to have a relatively small diagnostic value. Although our 
meta-analysis only searched two databases, PubMed 
and Embase, our included references and the results of 
merged data for PCT were similar to the study by Wacker 
et al. (2013) who searched 7 databases (pooled sensitivity: 
0.79 vs. 0.77; pooled specificity: 0.78 vs. 0.79). Therefore, 
we believe that one of the major reasons for publication 
Table 1 Research results of biomarkers with at least 4 references
TP true positive, FP false positive, FN false negative, TN true negative
a Median (25% percentiles, 75% percentiles)
Test Studies Cut-off n TP FP FN TN AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
PCT 59 0.96 (0.5, 1.7) ng/mla 7376 3173 847 1060 2296 0.85 [0.82, 0.88] 0.79 [0.75, 0.83] 0.78 [0.74, 0.81]
CRP 45 84 (38, 140) mg/l 5654 2356 719 1014 1565 0.77 [0.73, 0.81] 0.75 [0.69, 0.79] 0.67 [0.58, 0.74]
IL‑6 22 138 (75, 220) pg/ml 3450 1376 403 625 1046 0.79 [0.75, 0.82] 0.72 [0.63, 0.80] 0.73 [0.67, 0.79]
sTREM‑1 8 123 (635, 594) pg/ml 831 406 82 126 217 0.85 [0.82, 0.88] 0.78 [0.66, 0.87] 0.78 [0.65, 0.87]
Presepsin 9 600 (415, 647) pg/ml 1510 777 155 168 410 0.88 [0.85, 0.90] 0.84 [0.79, 0.88] 0.77 [0.68, 0.84]
LBP 5 30 (24.35, 32) μg/ml 1136 305 208 191 432 0.71 [0.67, 0.75] 0.62 [0.53, 0.71] 0.70 [0.59, 0.79]
CD64 4 – 558 300 13 76 169 0.96 [0.94, 0.97] 0.87 [0.75, 0.94] 0.93 [0.87, 0.96]
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Table 2 The research results for the biomarkers with less than 4 references
Test References Cutoff value N TP FP FN TN AUC Sensitivity Specificity
Acute phase protein
AGP Xiao et al. (2015) 1462 mg/l 277 150 8 42 77 0.869 0.782 0.902
MBL Ruiz‑Alvarez et al. (2009) – 104 49 13 29 13 0.6 0.63 0.5
SAA Reichsoellner et al. (2014) 289.4 μg/ml 159 80 32 30 17 0.519 0.73 0.35
sPLA2‑IIA Tan et al. (2016) 2.13 μg/l 51 38 2 4 7 – 0.91 0.78
Biomarkers related to vaosdilation
Substance P Reichsoellner et al. (2014) 0.3 ng/ml 159 62 23 48 26 0.524 0.56 0.53
Cell marker biomarkers
CD64/CD16 Hsu et al. (2011) – 66 47 2 8 9 0.883 0.855 0.818
CD11C Lewis et al. (2015) 48.50% 103 67 4 16 16 0.89 0.807 0.8
sCD22 Jiang et al. (2015) 2.3 ng/ml 64 31 6 7 20 – 0.8158 0.7692
sCD163 Feng et al. (2012) 1.49 μg/ml 132 75 2 27 28 0.856 0.74 0.9333
sCD25 Matera et al. (2013) – 53 25 6 4 18 0.812 0.875 0.75
Coagulation biomarkers
protein C activity Ishikura et al. (2014) 47% 82 33 7 10 32 – 0.775 0.811
Thrombomodulin Reichsoellner et al. (2014) 0 ng/ml 159 30 9 80 40 0.543 0.27 0.81
Cytokine/chemokine biomarkers
IFN‑r Jekarl et al. (2014) 45 pg/ml 127 68 16 29 14 0.573 0.702 0.464
IFN‑r Matera et al. (2013) 9 pg/ml 52 13 7 15 17 0.486 0.4545 0.7
IL‑1 Jekarl et al. (2014) 30 pg/ml 128 38 8 59 23 0.554 0.394 0.75
IL‑10 Jekarl et al. (2014) 40 pg/ml 127 32 1 65 29 0.661 0.329 0.964
IL‑10 Matera et al. (2013) 3.05 pg/ml 52 22 5 6 19 0.767 0.7826 0.8
IL‑10 Reichsoellner et al. (2014) 1.9 ng/ml 159 25 16 85 33 0.508 0.23 0.67
IL‑12 Jekarl et al. (2014) 2 pg/ml 127 18 9 79 21 0.504 0.181 0.714
IL‑13 Jekarl et al. (2014) 40 pg/ml 128 85 23 12 8 0.508 0.872 0.25
IL‑17 Jekarl et al. (2014) 1.5 pg/ml 127 41 9 56 21 0.586 0.426 0.714
IL‑2 Jekarl et al. (2014) 35 pg/ml 127 87 24 10 6 0.534 0.894 0.214
IL‑2 Balc et al. (2003) 1288.5 pg/ml 83 22 22 13 26 0.641 0.63 0.55
IL22 Jekarl et al. (2014) 300 pg/ml 127 75 18 22 12 0.542 0.776 0.393
IL‑4 Jekarl et al. (2014) 25 pg/ml 127 85 24 12 6 0.516 0.872 0.214
IL‑5 Jekarl et al. (2014) 5 pg/ml 127 69 9 28 21 0.714 0.713 0.714
IL‑8 Balc et al. (2003) 31.5 pg/ml 83 24 21 11 27 0.663 0.68 0.57
IL‑8 Harbarth et al. (2001) 30 ng/ml 78 38 4 22 14 0.71 0.63 0.78
IL‑8 Reichsoellner et al. (2014) 507.2 pg/ml 160 50 11 61 38 0.625 0.45 0.77
IL‑9 Jekarl et al. (2014) 5 pg/ml 128 83 23 14 8 0.532 0.851 0.25
MIF Kofoed et al. (2007) 0.81 ng/ml 151 77 29 19 26 0.63 0.8 0.47
Osteopontin Vaschetto et al. (2008) 1.7 ng/ml 56 19 6 8 23 0.796 0.7 0.79
TNF‑α Balc et al. (2003) 11.5 pg/ml 83 19 16 16 32 0.607 0.55 0.66
TNF‑α Jekarl et al. (2014) 15 pg/ml 128 47 8 50 23 0.598 0.489 0.75
TNF‑α Li et al. (2013a, b) 9.75 pg/ml 52 26 4 12 10 0.796 0.68 0.71
Receptor biomarkers
DcR3 Hou et al. (2012) 2.85 ng/ml 67 23 14 1 29 0.896 0.958 0.674
DcR3 Kim et al. (2012) 3.24 ng/ml 48 24 4 1 19 0.958 0.96 0.826
PLA2‑II Mearelli et al. (2014) 6 ng/ml 80 58 8 2 12 0.851 0.97 0.6
suPAR Hoenigl et al. (2013) 7.9 ng/ml 132 34 18 21 59 0.726 0.62 0.77
suPAR Kofoed et al. (2007) 2.7 ng/ml 151 34 18 62 37 0.5 0.35 0.67
suPAR Reichsoellner et al. (2014) 7.6 ng/ml 160 61 7 50 42 0.66 0.55 0.86
Vascular endothelial biomarkers
Endocan Scherpereel et al. (2006) 1.2 ng/ml 70 52 0 11 7 0.923 0.825 1
sICAM‑1 de Pablo et al. (2013) 904 ng/ml 92 39 2 13 38 0.9 0.743 0.941
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bias in our meta-analysis was more likely the publication 
of studies with positive or expected results rather than 
negative results.
Except for CD64, the remaining six biomarkers pre-
sented significant heterogeneity. Because the cutoff 
value for the same biomarker often varied among dif-
ferent studies, the diverse cutoff values often led to the 
threshold effect as a source of heterogeneity. We used 
meta-regression analysis to explore the sources of hetero-
geneity, but no single factor could satisfactorily explain 
the origins of the heterogeneity, including sample size, 
publication year, patient age, patient sex, the proportion 
of patients with sepsis and the methodological quality. 
Although the heterogeneity among studies was signifi-
cant, we had stable results for sensitivity analysis. Moreo-
ver, the pooled diagnostic test results are consistent with 
the other meta-analysis results (Wacker et  al. 2013; Wu 
et al. 2012; Li et al. 2013a, b).
Research quality could be an important factor that 
affected the results. For example, because of limited sam-
ple sizes and narrow disease spectra, some studies could 
not represent the overall state of the patients. In addition, 
most of the studies did not use blinded methods, which 
may have resulted in the judgment of sepsis to be affected 
by the biomarker determination results. These deficien-
cies may affect the authenticity of results and also lead to 
heterogeneity among the studies.
In the review by Pierrakos and Vincent (2010), the 
researchers retrieved a large number of biomarkers related 
to sepsis and made a detailed classification of them. How-
ever, they did not collect all articles in accordance with the 
inclusion criteria, nor did they quantitatively evaluate the 
diagnostic value of biomarkers. Two systematic reviews 
by Wacker et al. (2013) and Wu et al. (2012) evaluated the 
diagnostic accuracy of two popular biomarkers to differen-
tiate sepsis from SIRS—PCT and sTREM-1, respectively—
but they did not include any other biomarkers. In addition, 
two other systematic reviews by Simon et al. (2004) and Li 
et al. (2013b) assessed whether biomarkers could diagnose 
bacterial infection rather than sepsis. Our review included 
almost all diagnostic trials for the differential diagnosis of 
septic patients from those with a SIRS of non-infectious 
origin published before September 2016. Inconsistent con-
trol groups from different studies that may result in het-
erogeneity were ruled out in our analysis, such as those 
including healthy individuals, infected patients without 
SIRS, febrile patients without SIRS and immunocompro-
mised patients. We believed the inconsistency of baselines 
Table 2 continued
Test References Cutoff value N TP FP FN TN AUC Sensitivity Specificity
Other biomarkers
Ang 2 Mearelli et al. (2014) 3.2 ng/ml 80 49 12 11 8 0.581 0.82 0.4
Biotin Reichsoellner et al. (2014) 70.4 pg/ml 159 55 9 55 40 0.646 0.5 0.81
C2 Ruiz‑Alvarez et al. (2009) – 104 6 3 72 23 0.5 0.08 0.9
C3 Sungurtekin et al. (2006) 54 mg/dL 99 25 22 16 36 0.566 0.61 0.625
C3a Selberg et al. (2000) 540 ng/ml 33 19 2 3 9 0.9 0.86 0.8
C4 Sungurtekin et al. (2006) 28 mg/dL 99 32 36 9 22 0.544 0.78 0.382
cf‑DNA Garnacho‑Montero et al. (2014) 2850GE/ml 81 41 20 11 9 0.51 0.7931 0.3023
cf‑DNA Hou et al. (2016) 493 pg/ml 67 23 13 1 30 0.856 0.9412 0.7059
Copeptin Battista et al. (2016) 23.2 pmol/l 90 47 3 17 23 – 0.74 0.87
Cystatin C Reichsoellner et al. (2014) 2.1 μg/ml 159 55 14 55 35 0.578 0.5 0.71
Delta neutrophil index Seok et al. (2012) 0.03% 174 93 1 34 46 0.88 – –
Elastase Selberg et al. (2000) 91 μg/ml 33 19 10 3 1 0.57 0.86 0.09
eosinophil Abidi et al. (2008) – 140 96 4 24 16 0.84 0.8 0.8
Fibronectin Reichsoellner et al. (2014) 377.4 μg/ml 159 59 15 51 34 0.384 0.54 0.69
Interferon‑induced protein 10 Mearelli et al. (2014) 19.5 ng/ml 80 16 0 44 20 0.666 0.27 1
leptin Farag et al. (2013) 38.05 ng/ml 30 14 0 1 15 –
Leptin Yousef et al. (2010) 38 ng/ml 74 36 5 4 29 – 0.912 0.85
miR‑143 Han et al. (2016) 15.9 ng/ml 198 81 8 22 87 – 0.786 0.916
miR‑146a Wang et al. (2013) – 18 6 1 4 7 0.813 0.6 0.875
miR‑15a Wang et al. (2012) – 198 113 2 53 30 0.858 0.683 0.944
NGAL Reichsoellner et al. (2014) 82 ng/ml 159 29 2 81 47 0.599 0.26 0.96
Peroxiredoxin4 Schulte et al. (2011) 4.5 U/l 79 32 7 11 29 0.824 – –
Thrombocytes Sungurtekin et al. (2006) – 99 27 17 14 41 0.656 0.659 0.707
Page 7 of 10Liu et al. SpringerPlus  (2016) 5:2091 
among the control groups would lead to incorrect assess-
ments of the diagnostic value of biomarkers.
The biomarker CD64, a cell surface marker, showed a 
high value for the differential diagnosis of sepsis and SIRS. 
However, this test requires flow cytometry and trained 
technical personnel, which limits its feasibility in clini-
cal applications. Obviously, its high cost means that the 
promotion of one biomarker will be limited in developing 
or poor countries. Therefore, we believe that a desirable 
biomarker for diagnosing sepsis should have the following 
features: high sensitivity and specificity, elevation in the 
early phase of the infection, low cost and rapid results.
Sepsis is defined as life-threatening organ dysfunction 
caused by a serious infection, according to a new interna-
tional expert consensus (Singer et al. 2016). Therefore, SIRS 
is not a part of the diagnostic criteria of sepsis according 
to the new guideline. However, previous studies on sep-
sis markers still have a certain reference value, such as for 
PCT, which is still widely used in the clinical setting. Sum-
marizing previous research can provide information for 
new research and guide the development of new studies.
For the objective assessment of the diagnostic value of 
septic biomarkers, future trials should compare new puta-
tive markers with classical biomarkers such as PCT and CRP 
in the same trial and follow the Standards for Reporting of 
Diagnostic Accuracy (Bossuyt et al. 2003). Moreover, medi-
cal journals should consider accepting more studies with 
negative or unintended results to avoid publication bias.
The present meta-analysis shows that plasma PCT, 
sTREM-1 and presepsin have moderate diagnostic util-
ity in differentiating sepsis from SIRS. Several biomarkers 
with high AUC values, including CD64, DcR3, endocan, 
sICAM-1 and C3a, need more studies with larger sample 
sizes and rigorous methodological designs to confirm the 
results. Not surprisingly, because sepsis is a non-specific 
clinical syndrome related to serious microorganism infec-
tion and uncontrolled immune responses, it is less likely that 
one biomarker could satisfactorily differentiate sepsis from 
SIRS patients. In clinical practice, in addition to the dynamic 
changes of one septic biomarker, doctors should incorpo-
rate biomarkers with medical history, clinical symptoms, 
physical signs and other tests related to infection when diag-
nosing sepsis. In the future, biomarkers with better diagnos-
tic value and combined diagnosis with multiple biomarkers 
are expected to solve the challenge of the diagnosis of sepsis.
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